FDA places full clinical hold on Aardvark’s drug for extreme hunger in Prader-Willi syndrome
May 14 (Reuters) – Aardvark Therapeutics on Thursday said the U.S. Food and Drug Administration placed a full clinical hold on its drug to treat extreme hunger linked to the rare disorder Prader-Willi syndrome, halting all late-stage trials. Shares of the company fell about 14% in after-hours trading. Aardvark had paused enrollment and dosing in February after it found heart-related side effects in healthy volunteers given higher-than-planned doses of the […]